Share on StockTwits

Cytomedix (NASDAQ:CMXI) CFO Steven A. Shallcross purchased 27,500 shares of Cytomedix stock in a transaction dated Tuesday, August 26th. The stock was purchased at an average cost of $0.38 per share, with a total value of $10,450.00. Following the purchase, the chief financial officer now directly owns 79,500 shares of the company’s stock, valued at approximately $30,210. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Shares of Cytomedix (NASDAQ:CMXI) traded up 0.80% on Wednesday, hitting $0.38. 76,400 shares of the company’s stock traded hands. Cytomedix has a 1-year low of $0.33 and a 1-year high of $0.68. The stock’s 50-day moving average is $0.39 and its 200-day moving average is $0.46. The company’s market cap is $47.3 million.

Cytomedix, Inc is a United States-based company that develops biologically active regenerative therapies for wound and tissue repair.

Receive News & Ratings for Cytomedix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytomedix Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.